Following publication of the results of the PROLONG trial, The American College of Obstetricians and Gynecologists (ACOG) and the Society of Maternal Fetal Medicine Specialists (SMFM) have each released statements…
The Society for Maternal-Fetal Medicine (SMFM) has released a statement addressing the use of 17-alpha hydroxyprogesterone caproate (17-OHPC) therapy to prevent preterm birth (PTB) out of concern that women who…
OBJECTIVE: To promote use of progestogen therapy to reduce premature births in Ohio by 10%. METHODS: The Ohio Perinatal Quality Collaborative initiated a quality improvement project in 2014 working with…
Read More from ACOG Study: A Statewide Progestogen Promotion Program in Ohio
The Oklahoma Health Care Authority (OHCA) is expanding coverage of Makena® and vaginal progesterone effective August 1, 2016. The expanded coverage is an effort to decrease the number of preterm…
Read More from OHCA Provider Letter: Makena® and Vaginal Progesterone Coverage